AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:18 2025-01-17 am EST			5-day change	1st Jan Change
10,938.00 ^GBX	+0.87%		-0.40%	+4.49%

06:45pm	AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway	DJ
Jan. 17	Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	MT

Trump-induced Pharma fears shouldn't be long-lived

November 19, 2024 at 11:16 am EST

This Alphavalue article, the European leader in independent research, is only available to subscribers .

Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about AstraZeneca PLC

AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway	06:45pm	DJ
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	Jan. 17	MT
USA: 15 new drugs on the negotiation list	Jan. 17	CF
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	Jan. 17	MT
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	Jan. 17	MT
AstraZeneca overhauls management of its China division, FT reports	Jan. 17	RE
Astrazeneca Says Mantle Cell Lymphoma Combination Treatment Receives FDA Approval	Jan. 17	MT
FTSE 100 : Merger murmurs and Chinese data boost stocks	Jan. 17
AstraZeneca's Calquence gets US approval for mantle cell lymphoma	Jan. 17	AN
AstraZeneca: Calquence approved for LCM by the FDA	Jan. 17	CF
Stocks called up but UK retail sales miss forecasts	Jan. 17	AN
AstraZeneca Gets US FDA Nod for Lymphocytic Leukemia Treatment Calquence	Jan. 17	MT
Astrazeneca Announces Approval of Calquence (Acalabrutinib) in Combination with Bendamustine and Rituximab in the US for the Treatment of Adult Patients	Jan. 17	CI
Cellectis Files for Resale of 44 Million Company Shares by AstraZeneca	Jan. 15	MT
ASTRAZENECA : JP Morgan reaffirms its Buy rating	Jan. 15	ZD
Stockholm Bullets - Millicom rises on new dividend policy	Jan. 15	FW
Hutchmed lung cancer treatment Orpathys approved in China	Jan. 14	AN
Two experts give tips on dividend portfolios	Jan. 14	FW
Swedish stocks in North America - Autoliv up 1.1 percent	Jan. 14	FW
Hutchmed Announces NMPA Full Approval for Orpathys (Savolitinib) in China for Patients with Locally Advanced or Metastatic Met Exon 14 NSCLC	Jan. 13	CI
Philips CEO sees subdued China sales this year	Jan. 13	RE
Global markets live: Apple, Johnson & Johnson, Meta, Amazon, The Hershey, Eli Lilly...	Jan. 13
Synthego Signs Strategic Agreement with Astrazeneca to License CRISPR Gene Editing Enzyme	Jan. 13	CI
Astrazeneca Receives Priority Review for Datopotamab Deruxtecan in Non-Small Cell Lung Cancer	Jan. 13	MT
ASTRAZENECA : Goldman Sachs reiterates its Buy rating	Jan. 13	ZD

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Employees

89,900

Sector

Pharmaceuticals

Calendar

2025-02-06 - Q4 2024 Earnings Release

More about the company